KR102524594B1 - 시스테인 프로테아제 - Google Patents

시스테인 프로테아제 Download PDF

Info

Publication number
KR102524594B1
KR102524594B1 KR1020177025524A KR20177025524A KR102524594B1 KR 102524594 B1 KR102524594 B1 KR 102524594B1 KR 1020177025524 A KR1020177025524 A KR 1020177025524A KR 20177025524 A KR20177025524 A KR 20177025524A KR 102524594 B1 KR102524594 B1 KR 102524594B1
Authority
KR
South Korea
Prior art keywords
ala
lys
leu
gly
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177025524A
Other languages
English (en)
Korean (ko)
Other versions
KR20170110153A (ko
Inventor
크리스티안 셸만
소피아 야르눔
엠마 노르달
Original Assignee
한사 바이오파마 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한사 바이오파마 에이비 filed Critical 한사 바이오파마 에이비
Publication of KR20170110153A publication Critical patent/KR20170110153A/ko
Application granted granted Critical
Publication of KR102524594B1 publication Critical patent/KR102524594B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/2201—Streptopain (3.4.22.10)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
KR1020177025524A 2015-02-12 2016-02-12 시스테인 프로테아제 Active KR102524594B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1502305.4 2015-02-12
GB201502305A GB201502305D0 (en) 2015-02-12 2015-02-12 Protein
PCT/EP2016/053054 WO2016128559A1 (en) 2015-02-12 2016-02-12 Cysteine protease

Publications (2)

Publication Number Publication Date
KR20170110153A KR20170110153A (ko) 2017-10-10
KR102524594B1 true KR102524594B1 (ko) 2023-04-21

Family

ID=52781455

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177025524A Active KR102524594B1 (ko) 2015-02-12 2016-02-12 시스테인 프로테아제

Country Status (28)

Country Link
US (3) US10758597B2 (https=)
EP (2) EP3256579B1 (https=)
JP (1) JP6879921B2 (https=)
KR (1) KR102524594B1 (https=)
CN (2) CN107532158A (https=)
AU (1) AU2016217801B2 (https=)
BR (1) BR112017017286A2 (https=)
CA (1) CA2976016C (https=)
CL (1) CL2017002066A1 (https=)
CO (1) CO2017009060A2 (https=)
DK (1) DK3256579T5 (https=)
EA (1) EA035896B1 (https=)
ES (1) ES2962794T3 (https=)
FI (1) FI3256579T3 (https=)
GB (1) GB201502305D0 (https=)
HR (1) HRP20231496T1 (https=)
HU (1) HUE064122T2 (https=)
IL (1) IL253939B (https=)
LT (1) LT3256579T (https=)
MX (1) MX391632B (https=)
MY (1) MY187486A (https=)
PL (1) PL3256579T3 (https=)
PT (1) PT3256579T (https=)
RS (1) RS64840B1 (https=)
SG (1) SG11201706349YA (https=)
SI (1) SI3256579T1 (https=)
WO (1) WO2016128559A1 (https=)
ZA (1) ZA201705114B (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CN108410798A (zh) * 2018-03-27 2018-08-17 福建三造血技术有限公司 细胞分离用微珠洗脱液及配制方法
MX2020010465A (es) 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.
AU2019247748A1 (en) 2018-04-03 2020-10-08 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
EP3774852A1 (en) 2018-04-03 2021-02-17 Stridebio, Inc. Antibody-evading virus vectors
WO2020102740A2 (en) * 2018-11-16 2020-05-22 Spark Therapeutics, Inc. Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CA3127950A1 (en) * 2019-01-28 2020-08-06 Duke University Compositions and methods for evading humoral immunity
AR118465A1 (es) 2019-03-21 2021-10-06 Stridebio Inc Vectores de virus adenoasociados recombinantes
DE102019112558A1 (de) 2019-05-14 2020-11-19 Claas Selbstfahrende Erntemaschinen Gmbh Verfahren zur Wartung und/oder Reparatur einer landwirtschaftlichen Arbeitsmaschine
WO2021067598A1 (en) 2019-10-04 2021-04-08 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
JP2022551739A (ja) 2019-10-17 2022-12-13 ストライドバイオ，インコーポレイテッド ニーマン・ピック病ｃ型の治療のためのアデノ随伴ウイルスベクター
US12611436B2 (en) 2019-10-17 2026-04-28 Sarepta Therapeutics, Inc. AAV transfer cassette
SG11202110968VA (en) 2019-12-06 2021-10-28 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
IL325936A (en) * 2020-01-22 2026-03-01 Spark Therapeutics Inc Compositions and methods for enhancing or improving transduction of gene therapy vectors and removing or reducing immunoglobulins
JP2023514204A (ja) 2020-02-14 2023-04-05 ウルトラジェニックス ファーマシューティカル インコーポレイテッド Ｃｄｋｌ５欠損障害を処置するための遺伝子治療
GB202002072D0 (en) 2020-02-14 2020-04-01 Hansa Biopharma AB immunoglobulin detection and associated therapies
GB202003129D0 (en) 2020-03-04 2020-04-15 Hansa Biopharma AB Conditioning regimen for transplant of stem cells
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
GB202007431D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
EP4162951A4 (en) 2020-06-05 2024-07-10 Shanghai Bao Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMPOSITION OF ENZYMES AND VIRUSES AND ASSOCIATED APPLICATION
WO2021254479A1 (zh) * 2020-06-18 2021-12-23 上海宝济药业有限公司 一种免疫球蛋白降解酶IdeE的突变体
AU2021328475A1 (en) 2020-08-19 2023-03-16 Sarepta Therapeutics, Inc. Adeno-associated virus vectors for treatment of Rett syndrome
CN120078887A (zh) * 2020-09-21 2025-06-03 上海宝济药业股份有限公司 一种药物组合及其应用
CA3195177A1 (en) 2020-10-07 2022-04-14 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i)
WO2022221529A1 (en) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
FR3125965B1 (fr) * 2021-08-05 2024-06-21 Mc Saf Conjugués anticorps-médicament
US20250019721A1 (en) 2021-08-11 2025-01-16 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating a muscular dystrophy
US20250325640A1 (en) 2021-11-15 2025-10-23 Hansa Biopharma AB Methods for enhancing adoptive cell transfer immunotherapies
JP2024546152A (ja) 2021-12-16 2024-12-17 上海宝済薬業股▲ふん▼有限公司 免疫グロブリン分解酵素による切断に対抗するＦｃ変異体
EP4275701A1 (en) 2022-05-13 2023-11-15 Hansa Biopharma AB Conditioning regimen for cell transplant
EP4302770A1 (en) 2022-07-08 2024-01-10 Hansa Biopharma AB Regimen for enzymatic desensitisation
WO2024057095A1 (en) 2022-09-14 2024-03-21 Genovis Ab Mutant protease
EP4349365A1 (en) 2022-10-07 2024-04-10 Hansa Biopharma AB Co-treatment for gene therapy
CN115873833B (zh) * 2022-11-08 2024-08-16 上海泰昶生物技术有限公司 生产免疫球蛋白g降解酶的工程菌株和工艺
CN115998690B (zh) * 2022-11-10 2024-07-26 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺
AU2023383441A1 (en) 2022-11-18 2025-06-05 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
WO2024148276A1 (en) 2023-01-06 2024-07-11 Seismic Therapeutic, Inc. Protease variants and uses thereof
EP4687953A2 (en) * 2023-03-29 2026-02-11 Cyrus Biotechnology, Inc. Ides variant proteins and methods of using the same
WO2025103235A1 (zh) * 2023-11-13 2025-05-22 上海宝济药业股份有限公司 一种免疫球蛋白降解酶IdeE的突变体
WO2025226891A1 (en) * 2024-04-26 2025-10-30 Spark Therapeutics, Inc. Nucleic acid encoding ides
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
CN118497176B (zh) * 2024-07-16 2025-01-21 苏州康聚生物科技有限公司 一种免疫球蛋白降解酶
GB202413764D0 (en) 2024-09-18 2024-10-30 Genovis Ab Immunoglobulin proteases and their uses
GB202414654D0 (en) 2024-10-04 2024-11-20 Hansa Biopharma AB Regimen for vector-based therapies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102001427B1 (ko) 2011-09-13 2019-07-18 게노비스 에이비 스트렙토코쿠스 피오게네스 유래의 엔도글리코시다아제 및 그의 이용방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
EP0857175A1 (en) * 1995-10-23 1998-08-12 Incyte Pharmaceuticals, Inc. Novel human cysteine protease
CA2421278A1 (en) * 1998-03-11 1999-09-16 Genentech, Inc. Novel polypeptides and nucleic acids encoding the same
AU2002216863B8 (en) 2000-12-21 2008-03-20 Id Biomedical Corporation Streptococcus pyogenes antigens and corresponding DNA fragments
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
PL1901773T3 (pl) * 2005-06-09 2012-09-28 Hansa Medical Ab Zastosowanie proteinazy IDES (Z S. Pyogenes) do leczenia chorób autoimmunologicznych oraz odrzutów przeszczepu
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
GB0624874D0 (en) * 2006-12-13 2007-01-24 Hansa Medical Ab Treatment
DK2190984T3 (da) 2007-09-14 2013-12-02 Genovis Ab Fremgangsmåder og kits til oprensning og påvisning af glycosyleret IgG
US20110020403A1 (en) 2007-12-13 2011-01-27 Bengt Guss immunizing composition
ES2388017T3 (es) 2007-12-21 2012-10-05 Roche Glycart Ag Ensayo de estabilidad de anticuerpos
EP2394173B1 (en) 2009-02-09 2015-03-25 Roche Glycart AG Immunoglobulin glycosylation pattern analysis
WO2011149419A1 (en) 2010-05-26 2011-12-01 Intervacc Ab Vaccine against streptococcal infections based on recombinant proteins
GB201201314D0 (en) 2012-01-26 2012-03-07 Isis Innovation Composition
GB201316744D0 (en) 2013-09-20 2013-11-06 Genovis Ab Method
GB201413240D0 (en) 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102001427B1 (ko) 2011-09-13 2019-07-18 게노비스 에이비 스트렙토코쿠스 피오게네스 유래의 엔도글리코시다아제 및 그의 이용방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FEMS Microbiol Lett, 2006, Vol.262, pp.230-235

Also Published As

Publication number Publication date
EP3256579A1 (en) 2017-12-20
HUE064122T2 (hu) 2024-03-28
CN113564150B (zh) 2024-09-17
SG11201706349YA (en) 2017-09-28
CL2017002066A1 (es) 2018-02-02
CA2976016C (en) 2023-08-29
CN107532158A (zh) 2018-01-02
IL253939A0 (en) 2017-10-31
EP4265719A1 (en) 2023-10-25
RS64840B1 (sr) 2023-12-29
MX2017010389A (es) 2017-12-07
IL253939B (en) 2020-01-30
CN113564150A (zh) 2021-10-29
US20180037962A1 (en) 2018-02-08
US20230302100A1 (en) 2023-09-28
ES2962794T3 (es) 2024-03-21
LT3256579T (lt) 2023-11-27
AU2016217801A1 (en) 2017-08-10
PT3256579T (pt) 2023-11-23
EA201791775A1 (ru) 2018-02-28
CO2017009060A2 (es) 2018-01-16
MY187486A (en) 2021-09-24
AU2016217801B2 (en) 2022-03-17
US20200179497A1 (en) 2020-06-11
GB201502305D0 (en) 2015-04-01
FI3256579T3 (fi) 2023-11-13
PL3256579T3 (pl) 2024-02-26
JP6879921B2 (ja) 2021-06-02
US10758597B2 (en) 2020-09-01
JP2018510622A (ja) 2018-04-19
DK3256579T3 (en) 2023-11-20
HRP20231496T1 (hr) 2024-03-01
WO2016128559A1 (en) 2016-08-18
DK3256579T5 (en) 2024-10-14
MX391632B (es) 2025-03-21
CA2976016A1 (en) 2016-08-18
KR20170110153A (ko) 2017-10-10
US11524057B2 (en) 2022-12-13
EP3256579B1 (en) 2023-08-30
BR112017017286A2 (pt) 2018-04-17
SI3256579T1 (sl) 2024-01-31
EA035896B1 (ru) 2020-08-27
ZA201705114B (en) 2024-01-31
NZ733962A (en) 2024-07-05

Similar Documents

Publication Publication Date Title
KR102524594B1 (ko) 시스테인 프로테아제
KR102524613B1 (ko) 시스테인 프로테아제
JP7770341B2 (ja) システインプロテアーゼ
HK1240611A1 (en) Cysteine protease
HK1240611B (en) Cysteine protease
HK1240619A1 (en) Cysteine protease
HK1240619B (en) Cysteine protease

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4